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Autism spectrum disorder is a neurodevelopmental disorder characterized by impairments in social interactions,
reduced verbal communication abilities, stereotyped repetitive behaviors, and restricted interests. It is a complex
condition caused by genetic and environmental factors; the high heritability of this disorder supports the presence of a
significant genetic contribution. Many studies have suggested that copy-number variants contribute to the etiology of
autism spectrum disorder. Recently, copy-number variants of the nephronophthisis 1 gene have been reported in
patients with autism spectrum disorder. To the best of our knowledge, only six autism spectrum disorder cases with
duplications of the nephronophthisis 1 gene have been reported. These patients exhibited intellectual dysfunction,
including verbal dysfunction in one patient, below-average verbal intellectual ability in one patient, and intellectual
disability in four patients.
In this study, we identified nephronophthisis 1 duplications in two unrelated Japanese patients with autism
spectrum disorder using a high-resolution single-nucleotide polymorphism array. This report is the first to describe
a nephronophthisis 1 duplication in an autism spectrum disorder patient with an average verbal intelligence
quotient and an average performance intelligence quotient. However, the second autism spectrum disorder
patient with a nephronophthisis 1 duplication had a below-average performance intelligence quotient. Neither
patient exhibited physical dysfunction, motor developmental delay, or neurological abnormalities. This study
supports the clinical observation of nephronophthisis 1 duplication in autism spectrum disorder cases and might
contribute to our understanding of the clinical phenotype that arises from this duplication.
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Autism spectrum disorder (ASD) is a neurodevelopmental
condition characterized by compromised social interac-
tions, reduced verbal communication abilities, stereotyped
repetitive behaviors, and restricted interests [1]. The
prevalence of ASD is estimated to be 62 in 10,000 individ-
uals, and the number of diagnosed cases has increased in
the past decade [2,3]. The etiologies of ASD are complex* Correspondence: hashimor@psy.med.osaka-u.ac.jp
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unless otherwise stated.and unclear, and both genetic and environmental factors
are hypothesized to be contributors. The following gen-
etic factors have been reported to be associated with of
ASD: 2,135 non-syndromic autism-related genes, 99
syndromic autism-related genes, 4,544 copy-number
variations (CNVs), and 158 linked regions [4]. Copy-
number alterations in the nephronophthisis 1 gene
(NPHP1; NM_000272.3) which is located in the 2q13 re-
gion have been associated with ASD [5-9]. The genomic
region that surrounds NPHP1 is flanked by two inverted
low-copy repeats (LCRs), which include 45-kb direct re-
peats; therefore, deletion or duplication can easily occur
in this region via non-allelic homologous recombin-
ation, which results in NPHP1 copy-number changesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Yasuda et al. Annals of General Psychiatry 2014, 13:22 Page 2 of 5
http://www.annals-general-psychiatry.com/content/13/1/22[10]. In humans, homozygous or compound heterozy-
gous deletions and loss-of-function mutations in NPHP1
cause ciliopathies such as juvenile nephronophthisis
(MIM# 256100), Joubert syndrome type 4 (MIM# 609583),
and Senior-Loken syndrome 1 (MIM# 266900) [10,11]. In
a 2007 study, 1 of 14 patients with Joubert syndrome type
4 exhibited ASD [12]. Additional studies have confirmed
the presence of NPHP1 deletions in individuals with ASD
[5-8]. Duplication of the NPHP1 gene has been identified
in ASD patients and controls [12,13]. Whether the CNV in
this gene is a normal variant is unknown [7,13]. Six indi-
viduals with ASD have been reported to have NPHP1
duplications confirmed by a validation analysis [7,13,14]
(Table 1). The NPHP1 gene and its product are associated
with the primary cilium and basal body (PC/BB) and
subcellular organelles [15]. The PC/BB control diverse
cellular processes such as cell division, differentiation,
migration, and planar cell polarity through signaling
pathways [11,15]. These molecular findings and re-












Patient 1 ASD 24 Male FIQ 110
PIQ 98
VIQ 117






ISCA00000020 ASD NA NA Intellectual
disability was
detected
ISCA00000128 ASD NA NA Intellectual
disability was
detected.
ISCA00000949 ASD NA NA Intellectual
disability was
detected























ASD autism spectrum disorder, PDD pervasive developmental disorder, ADHD atten
PIQ performance IQ, VIQ verbal IQ.altered NPHP1 gene support the hypothesis that the
gene is associated with brain development and cog-
nitive impairment. However, no functional study has
reported a correlation between the NPHP1 gene and
intelligence.
Of the six individuals who have been identified with
ASD and NPHP1 duplications, one patient had a verbal
intelligence quotient (VIQ) that was below average [7],
one patient exhibited verbal dysfunction [13], and four
other patients had intellectual disabilities [14]. We identi-
fied an NPHP1 duplication in two unrelated Japanese pa-
tients with ASD using a high-resolution single-nucleotide
polymorphism array. One of these patients had a normal
VIQ and performance IQ (PIQ). The other ASD patient
had a normal VIQ, with a PIQ that was below average. As
previously described, NPHP1 duplications have been ob-
served in a number of ASD cohorts. No reports have de-
lineated the clinical features of patients who harbor an
NPHP1 duplication. Clinical data from patients with ASD
will facilitate an understanding of the contribution of thisHP1 gene in our study and previous studies
Dysmorphic features Clinical profile
No dysmorphic features were
observed
No evidence of epilepsy was
observed. The neurological
examination was normal. The
function of visceral organs,
including the kidneys, was normal
No dysmorphic features were
observed
No evidence of epilepsy was
observed. The neurological
examination was normal. The
function of visceral organs,
including the kidneys, was normal
NA Developmental delay was observed
NA Developmental delay was observed
NA Developmental delay was observed
NA Developmental delay was observed
No dysmorphic features were
observed
No evidence of epilepsy was
observed
Mid-face hypoplasia, bilateral
epicanthal folds, long palpebral
fissures, synophrys, upturned nose
with a depressed nasal root and
retrognathia, and relative
macrocephaly were observed
Speech delay and abnormal skin
lesions were observed. The
neurological examination was
normal. Brain MRI was normal. A
renal ultrasound scan was normal
tion deficit hyperactivity disorder, NA not available, FIQ full-scale IQ,
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our knowledge, this report is the first to describe ASD
cases with NPHP1 duplications but without dysmorphic
features or intellectual dysfunction.Case presentation
Case 1
Patient 1 was a 24-year-old male with ASD. He was
born vaginally at 37 weeks and had a birth weight of
2,190 g (−1.43 standard deviation, SD); his mother had
pregnancy-induced hypertension. The family history
was unremarkable. The patient began to walk independ-
ently at 15 months of age. During his childhood, he had
difficulty with social communication and exhibited dis-
tress during the first grade from changes in the elemen-
tary school environment. He was first seen in the clinic
when he was in the fifth grade because of the develop-
ment of a tic, which improved without treatment. When
the patient was a college senior, his symptoms wors-
ened, and he was first diagnosed with ASD at 24 years
of age by a child psychiatrist. At 26 years of age, his in-
tellectual ability was within the normal range (a full-
scale IQ (FIQ) of 110, a VIQ of 117, and a PIQ of 98).
He was not dysmorphic. The neurological examination
and the functioning of visceral organs, including the
kidneys, were normal. Brain magnetic resonance im-
aging (MRI) at 24 years of age was reported as normal.
His parents were phenotypically normal.Case 2
Patient 2 was a 33-year-old male with ASD. He was de-
livered by Cesarean section, and neonatal asphyxia was
caused by dystocia following an uneventful pregnancy.
His birth weight was 4,070 g (+2.6 SD). The patient de-
veloped tics in elementary school and had difficulty with
social communication. He was frequently a victim of
bullying and exhibited distress over changes in his en-
vironment. At 17 years of age, he was diagnosed with
schizophrenia, which resulted in repeated hospitaliza-
tions. When he was 33 years old, a new doctor noticed
his communication impairments and stereotyped behav-
iors. The doctor initially referred him to a child psych-
iatrist, and his diagnosis was changed to ASD and
schizophrenia.
At 36 years of age, his intellectual ability was within
the normal range (FIQ, 80; VIQ, 86); his PIQ was below
average (PIQ, 76). He had no dysmorphic features. The
neurological examination and the functioning of visceral
organs, including the kidneys, were normal. Brain MRI
at 33 years of age was reported as normal. His father
was phenotypically normal, whereas his mother was af-
fected with schizotypal personality disorder.Assessment of ASD
The patients were diagnosed by at least two trained child
psychiatrists and/or child neurologists according to the
criteria of the Diagnostic and Statistical Manual of Men-
tal Disorders, 5th Edition (DSM-5). The assessments
were performed using unstructured or semi-structured
behavioral observation and interviews with the patients
and their parents or caregivers [16]. Additionally, the
participants met the ASD criteria of the Autism Diag-
nostic Interview-Revised (ADI-R) [17]. The Pervasive
Developmental Disorders Autism Society Japan Rating
Scale (PARS) [18] and the Japanese version of the Asper-
ger’s Questionnaire (AQ-J) [19] were used to evaluate
ASD-specific behaviors and symptoms. The patients
were recruited at Osaka University Hospital.
Cognitive tests
The Japanese version of the full-scale Wechsler Adult
Intelligence Scale-III (WAIS-III) [20] was used to obtain
the IQ data.
Copy-number analysis
Genomic DNA was extracted from whole blood using the
QIAamp DNA Blood Maxi Kit (Qiagen, Hilden, Germany).
The biological parentage was confirmed using nine poly-
morphic microsatellite markers (D1S450, D1S206, D5S630,
D5S410, D9S285, D9S1776, D13S217, D14S276, and
D14S985). The amplicons were separated on a Genetic
Analyzer 3500 (Life Technologies, Inc., Carlsbad, CA, USA)
and were analyzed using GeneMapper software, version 4.1
(Life Technologies, Inc.).
CNVs were analyzed using the CytoScan™ HD array
(Affymetrix, Santa Clara, CA, USA) and Chromosome
Analysis Suite (ChAS) software, version 1.2 (Affymetrix)
according to the manufacturer’s instructions. The detec-
tion conditions in ChAS were set as follows: a confi-
dence value of 90%, 20 contiguous probes, and a size
larger than 100 kb for duplications; and a confidence
value of 89%, 20 contiguous markers, and a size larger
than 10 kb for deletions. The copy-number alterations
detected by the microarray analysis were validated by
quantitative real-time polymerase chain reaction (PCR)
using Rotor-Gene Q (Qiagen). STXBP1 and FBN1 genes
were used as reference genes. The PCR conditions and
primer sequences are available upon request. Quantita-
tive PCR was conducted in duplicate.
Using a high-resolution microarray analysis, we found
a 110-862-kb duplication that involved the NPHP1 gene
in these two patients (minimum, chr2 110, 873, 834-110,
983, 413 bp and maximum, chr2 110, 504, 317-111, 365,
995 bp based on the University of California Santa Cruz
Genome Browser, build 37 [hg19]). The entire NPHP1
gene and the partial MALL gene are protein-coding
genes that are located between two LCRs (see Additional
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novo duplications in both patients using quantitative real-
time PCR with DNA (see Additional file 2: Figure S2).
Additionally, the biological parentage was confirmed.
Conclusions
We examined two Japanese ASD cases with NPHP1 du-
plications and delineated their clinical features. Previous
studies have described ASD cases with NPHP1 duplica-
tions; however, these cases were associated with FIQ or
VIQ impairment [7,13,14]. By contrast, we found that
one patient with ASD in this study had an average intel-
lectual ability. There is a possibility that the difference in
cognitive ability could be caused by other genetic abnor-
malities and not by the NPHP1 gene. Details of
microarray-based genomic profiling in the region of the
duplication of the NPHP1 gene are shown in our two
cases and six cases reported in previous studies (Add-
itional file 3: Table S1). No specific gene, which is able
to distinguish between our case with normal range of in-
tellectual ability and cases in our study and previous
studies with intellectual impairment, was found. We
found a paternal CNV in our two cases in different re-
gion, where the genes did not exist, suggesting that no
other gene might cause functional impact on this cogni-
tive phenotype. On the other hand, the information of
other CNVs present in six cases with intellectual impair-
ment in previous studies was not available. It is possible
that unknown CNVs other than duplication of the
NPHP1 gene might be responsible for intellectual im-
pairment in previous six cases.
One of the six previously described ASD cases had
dysmorphic features [13]. An additional ASD case did
not exhibit dysmorphic features [7], and data regarding
dysmorphic features were not available for the other
ASD cases [14] (Table 1). Our cases did not exhibit dys-
morphic features. These findings suggest that patients
with ASD and an NPHP1 duplication might not exhibit
dysmorphic features. Previously described cases with
NPHP1 duplications that were not associated with ASD
demonstrated various phenotypes (Table 1) [13,21]. It is
unclear whether an NPHP1 duplication is the causative
factor of ASD.
The patients in this study had ASD features from early
childhood; however, they were not diagnosed with ASD
until adulthood. This delayed diagnosis might have re-
sulted from the patients having an average FIQ. Individ-
uals with ASD vary in intelligence, which ranges from
having an intellectual disability to a high IQ [22]. Indi-
viduals with a normal or high IQ are frequently difficult
to diagnose as having ASD. In addition, the diagnosis of
ASD might not have been well understood during their
childhood years, which could have resulted in a delayed
diagnosis. Patient 2 suffered from schizophrenia andsecondary ASD; a high rate of comorbidity with other
psychiatric disorders has been observed in adults with
ASD [23]. However, it is not possible to confirm whether
this patient had two independent disorders. A duplica-
tion of the NPHP1 gene occurred in both cases in this
study; however, this duplication has been observed in
controls. To clarify whether the NPHP1 gene is a
disease-causing gene or a disease-associated factor, fur-
ther investigation of this locus in larger samples is
warranted.
Consent
A description of the study was provided to each subject,
and written informed consent was obtained from each
subject regarding publication of this case report and any
accompanying data. Peripheral blood samples from the
patients and their families (when available) were col-
lected after obtaining informed consent. This study was
performed according to the Declaration of Helsinki of
the World Medical Association; it was approved by the
ethics committee at Osaka University and the institu-
tional review board of Yokohama City University School
of Medicine. Copies of the signed informed consent
forms are available for review by the Editor-in-Chief of
this journal.
Additional files
Additional file 1: Figure S1. De novo 2p13 duplication in two
individuals with ASD. Single-nucleotide polymorphism array profiles in
the 2p13 region are shown for a control patient (top), patient 1 (second
row), and patient 2 (third row). The location of NPHP1, other genes, and
low-copy repeats (LCRs) (gray box) are depicted based on the University
of California Santa Cruz Genome Browser, build 37 (hg19) (bottom).
Additional file 2: Figure S2. Confirmation of the de novo 2p13
duplication in two individuals with ASD. Gene expression was
determined by quantitative real-time PCR, and the relative concentration
of NPHP1 is shown on the Y-axis. Duplication was confirmed in the two
patients (Pt 1 and Pt 2) with ASD.
Additional file 3: Table S1. Details of microarray-based genomic
profiling in individuals with a duplication of the NPHP1 gene in this and
previous studies.
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